At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

Researchers from the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, ...

Common respiratory condition nearly triples the risk of death in adults, new study finds A major study presented today at ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, ...

which reflect the latest evidence for RSV epidemiology, immunization practices, and product authorization and availability in Canada. Recommendations also take into account ethics, equity, feasibility ...

David Muscatello, an associate professor in infectious diseases epidemiology at UNSW's School of Population ... Last year, 42,668 cases of respiratory syncytial virus (RSV) were recorded in New South ...

The Allan Labor Government is keeping Victorian babies safe from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available free from tomorrow for eligible families until ...